Tag: Catabasis Pharmaceuticals

June 21, 2019

Catabasis Pharmaceuticals Presents Preclinical Data of Edasalonexent

Catabasis Pharmaceuticals (NASDAQ:CATB) has announced preclinical data for its edasalonexent in Phase 2 development to treat Duchenne musclar dystrophy (DMD)....